Roth IRAs let dividends compound tax-free forever, which makes them the ideal wrapper for names that spit out ordinary-income distributions taxed at your marginal rate outside the account. The four below yield…
Pfizer's payout looks like a safe harbor in a rough market, but the patent clock is ticking and the balance sheet leaves almost no room for error. Here is what actually has…
Chris Lange Holding high-yield dividend stocks like BDCs and REITs in the wrong account silently erases hundreds of dollars every year, and most investors never see it happening until they run the actual numbers.
Treasury yields are making income investors work harder than they have in years, and most dividend stocks no longer clear the bar. Six still do, but yield alone is the easy part…
Collecting $8,900 a month in retirement without selling shares sounds clean until you see what the biggest position in this seven-ticker setup actually pays when markets go quiet.
Pfizer's 5.91% yield draws most of the headlines, but a quietly rerated stock and a pipeline loaded with 2026 catalysts are building a separate case altogether for investors willing to look past…
Pfizer shareholders are collecting a 6% yield while the stock bleeds value, and the CEO just made a bold promise about keeping that payout alive through what could be the company's toughest…
Chris Lange Three blue-chip CFO swaps touched off double-digit stock rallies while Rivian's announcement landed with a thud. The difference comes down to one decision Rivian has yet to make.
Pfizer and Starbucks both raised their outlooks this summer, but a louder recovery and a quieter one are not the same thing, and for investors who need a portfolio to fund actual…
BioNTech's colorectal cancer vaccine just collapsed in a Phase 2 trial, dragging Moderna down with it despite last week's melanoma triumph, and the fallout is forcing investors to rethink how far mRNA…
Three famous dividend names trade well below their five-year highs while their CEOs publicly draw lines in the sand around the payout. Whether the cash flow actually backs that confidence is a…
Merck stock sits near analyst targets that fall short of $200, yet a compressed fall calendar of FDA decisions and a pivotal cancer vaccine readout could force Wall Street to rethink the…
Pfizer shares sit near a 52-week high after years of post-pandemic punishment, and now Wall Street analysts are quietly shifting their tone. Here is what the pipeline, the dividend, and the valuation…
Pfizer, Chevron, and AbbVie have already rewarded dividend investors with strong 2026 gains, but the bull case for 2027 pushes well beyond what Wall Street consensus currently projects, and the catalysts behind…
Hedge funds are quietly loading up on a battered pharma giant while yield hunters circle its once-near-7% dividend, but with a 14% rally already in the books and patent cliffs looming, the…
